PANORAMA DU M�DECIN 2011-11-01

[Benfluorex and valvular heart disease].

Christophe Tribouilloy, Antoine Jeu, Sylvestre Maréchaux, Yannick Jobic, Dan Rusinaru, Michel Andréjak

文献索引：Presse Med. 40(11) , 1008-16, (2011)

全文：HTML全文

摘要

Benfluorex is responsible of restrictive organic valvular regurgitations via one of its metabolites, the norfenfluramine. It has been withdrawn from the european market in June 2010. In France, about five millions of people have been exposed to benfluorex since its market launch in 1976. At the time of its market withdrawn, over 300,000 patients in France were taking the drug. Aortic and mitral valves are the most frequent involved. The prevalence of this type of valve damage is not yet known with accuracy. Severe regurgitations appear to be rare (less than one case per thousand exposed patients-year).Copyright © 2011 Elsevier Masson SAS. All rights reserved.

相关化合物

  • 盐酸苯氟雷司

相关文献：

[About the settlement of litigations concerning the harm caused by benfluorex (Mediator®)].

2013-04-01

[Presse Med. 42(4 Pt 1) , 411-8, (2013)]

[Reform Act on safety of drug and health products in France: announcement effect, strengthening or upheaval?].

2012-01-01

[Therapie. 67(1) , 1-10, (2012)]

Mediator scandal engulfs French compensation body.

2013-05-25

[Lancet 381(9880) , 1803, (2013)]

European legislators tighten rules on drug safety.

2012-01-01

[BMJ 345 , e6260, (2012)]

Can benfluorex induce congenital malformations?

2012-10-01

[Diabetes Metab. 38(4) , 373-4, (2012)]

更多文献...